immunotherapy breast cancer triple negative

Release time ：Nov-15,2024

Immunotherapy represents a novel approach in the treatment of triple-negative breast cancer (TNBC), a highly aggressive form of breast cancer that poses significant therapeutic challenges due to the absence of estrogen, progesterone, and HER2 receptors, rendering traditional endocrine and targeted therapies less effective. By harnessing the patient’s immune system to recognize and combat cancer cells, immunotherapy offers renewed hope for managing TNBC.

Therapeutic strategies for TNBC via immunotherapy include several mechanisms: immune checkpoint inhibitors that disrupt the signaling between cancer and immune cells, thereby enabling immune cells to detect and attack cancer cells; tumor vaccines that stimulate the immune system to produce antibodies specific to cancer cells, achieving a therapeutic effect; and additional modalities such as cytokine therapy and adoptive cell transfer, which also demonstrate some efficacy in TNBC. However, it is crucial to recognize that immunotherapy may not be appropriate for all TNBC patients and can potentially induce side effects, necessitating rigorous evaluation and monitoring prior to its application.

For individuals diagnosed with TNBC, timely medical intervention and professional treatment are paramount. During immunotherapy, adherence to medical guidance, regular follow-ups, and monitoring are essential to ensure treatment safety and efficacy. Moreover, maintaining healthy lifestyle habits and a positive attitude, along with active engagement in treatment, can significantly contribute to enhancing treatment outcomes and overall quality of life.